Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2006

View Archived Issues

Proof-of-concept milestone in phase Ib study of HCV-796

Milestone achieved in Evotec and Takeda's Alzheimer's disease collaboration

Chromos advances development of CHR-1103

NTx-265 yields recovery of lost neurological function in rodent model of stroke

Overcoming TKI resistance via ADAM inhibition

NNZ-2566 set to begin phase II for traumatic brain injury in 2007

Algeta and Affibody to develop novel targeted radiotherapeutics

New imaging agents for ocular disorders and cancer disclosed in recent GE and Yeda patents

HIV integrase inhibitor 364735 completes initial phase I study

Recent Tanabe and Neurogen patents report novel analgesic agents

Recent Tanabe and Dainippon patents describe new antidiabetic agents

Recent Tibotec and Pfizer patents report novel therapeutic agents for HIV infection

5F-203 triggers single-strand DNA breaks and cell cycle arrest in MCF7 cells

Favorable pharmacokinetics in monkeys warrant further development of Dioxolane T

TMC-278-ketoconazole interaction detailed in healthy subjects

Pharmacokinetics of apricitabine similar in HIV-positive and -negative subjects

Vicriviroc pharmacokinetics, phase II results reported

New data on TMC-114, TMC-125 and their combination presented

Safety and activity of fontolizumab evaluted in Crohn's disease patients

BB-10153 induces high rate of normal flow in ST elevation myocardial infarction

Actonel approved for men with osteoporosis

Remicade approved for expanded indication in psoriatic arthritis

Vasovist recommended for approval in Australia

Abilify Discmelt launched in U.S.

Plavix approved for use in patients with STEMI

Keppra approved in Europe for newly diagnosed epilepsy patients

Rhucin MAA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...